prevention; (13) reviews Center-wide acquisition and assistance operations to ensure adherence to law, policies, procedures, and regulations; (14) coordinates NCCDPHP requirements relating to small purchase procurement, material management, and interagency agreements; (15) in the conduct of these activities, maintains liaison with other CDC Centers/Institute/Offices, HHS, and other Federal agencies.

Dated: September 14, 1998.

Claire V. Broome,

Acting Director.

[FR Doc. 98–25392 Filed 9–22–98; 8:45 am]

BILLING CODE 4160–18–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Submission for OMB Review; Comment Request

Title: Child Care and Development Fund Plan for States and Territories (Supplement).

OMB No.: 0970–0114.

Description: The Child Care and Development Block Grant (CCDBG) Act of 1990 requires the States and Territories to submit a biennial Plan (ACF–118) in order to receive Federal funds. The statutorily required Plan provides the public and ACF with a description of, and assurances about, the States's Child Care Program. In 1996, the Personal Responsibility and Work Opportunity Reconciliation Act (PRWORA) provided additional fiscal resources for child care but required that the funds be spent in accordance with the provisions of the CCDBG Act. This supplement to the existing Plan reflects the changes made by PRWORA, and provides information to determine in State programs are administered in accordance with the applicable statutes and regulations. The Tribal Plan (ACF–118A) is not effected by this notice.

Respondents: State and Tribal Governments.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
ACF–118	56	1	4	112

Estimated Total Annual Burden Hours: 112.

Additional Information: Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Information Services, Division of Information Resource Management Services, 370 L'Enfant Promenade, SW, Washington, DC 20447, Attn: ACF Reports Clearance Officer.

OMB Comment: OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, 725 17th Street, NW, Attn: Ms. Wendy Taylor.

Dated: September 17, 1998.

Bob Sargis,

Acting Reports Clearance Officer.

[FR Doc. 98–25385 Filed 9–22–98; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Cardiovascular and Renal Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on October 22, 1998, 9 a.m. to 5:30 p.m., and October 23, 1998, 9 a.m. to 3 p.m.

Location: National Institutes of Health, Clinical Center, Bldg. 10, Jack Masur Auditorium, 9000 Rockville Pike, Bethesda, MD. Parking in the Clinical Center is reserved for Clinical Center patients and their visitors.

Contact Person: Joan C. Standaert, Center for Drug Evaluation and Research (HFD–110), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 419–259–6211, or John M. Treacy (HFD–21), 301–827–7001, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12533. Please call the Information Line for up-to-date information on this meeting.

Agenda: On October 22, 1998, the committee will discuss guidelines for the study of congestive heart failure. On October 23, 1998, the committee will discuss new drug application (NDA) 20–873, Hirulog (bivalirudin, The Medicine's Co.), injection for anticoagulation in patients undergoing percutaneous transluminal angioplasty.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by October 14, 1998. Oral presentations from the public will be scheduled between approximately 9 a.m. and 10 a.m. on October 23, 1998. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before October 14, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).